Author: Tom Wilemon
Sep. 24, 2021—The Meharry Medical College/Vanderbilt-Ingram Cancer Center/Tennessee State University Partnership has received renewed funding from the NCI to continue long-standing collaborations to eliminate cancer health disparities.
Sep. 23, 2021—Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
Sep. 10, 2021—Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
Aug. 19, 2021—Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
Aug. 12, 2021—A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Aug. 5, 2021—A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.
Jul. 15, 2021—Kristen Ciombor, MD, MSCI, is one of 10 physicians nationwide selected by the National Cancer Institute (NCI) for the 2021 Cancer Clinical Investigator Team Leadership Award.
Jul. 15, 2021—Susan G. Komen has announced breast cancer research grants totaling $14 million, including funding for three separate initiatives led by Vanderbilt-Ingram Cancer Center (VICC) researchers.
Jul. 14, 2021—Nancy Davis, MD, has been promoted to Vice President for Cancer Care Network and Strategy at Vanderbilt University Medical Center, a new position responsible for developing provider relationships with other health care systems and expanding access to oncology care throughout Tennessee and other states.
Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.